Disclosure of Adverse Clinical Trial Results—Should Legal Immunity Be Granted to Drug Companies?

American Journal of Bioethics 9 (8):45-47 (2009)
  Copy   BIBTEX

Abstract

This article has no associated abstract. (fix it)

Categories

Keywords

Reprint years

DOI

10.1080/15265160902939933

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 91,219

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

The Duty to Disclose Adverse Clinical Trial Results.S. Matthew Liao, Mark Sheehan & Steve Clarke - 2009 - American Journal of Bioethics 9 (8):24-32.
Evaluation of drug toxicity in clinical trials.Jacek Spławiński, Jerzy Kuźniar, Krzysztof Filipiak & Waldemar Zieliński - 2006 - Science and Engineering Ethics 12 (1):139-145.
Enhancing Informed Consent in Clinical Trials and Exploring Resistances to Disclosing Adverse Clinical Trial Results.John D. Banja & Boadie Dunlop - 2009 - American Journal of Bioethics 9 (8):39-41.
The Duty to Disclose (Even More) Adverse Clinical Trial Results.Nicole Hassoun - 2009 - American Journal of Bioethics 9 (8):33-34.
Clinical trials: Active control vs placebo — what is ethical?Jacek Spławiński & Jerzy Kuźniar - 2004 - Science and Engineering Ethics 10 (1):73-79.
Respecting Participant Autonomy and the Disclosure of Clinical Trial Results.Justin Oakley - 2009 - American Journal of Bioethics 9 (8):38-38.
Improving Subject Recruitment By Maintaining Truly Informed Consent: A Practical Benefit of Disclosing Adverse Clinical Trial Results.Kavita R. Shah & Frances R. Batzer - 2009 - American Journal of Bioethics 9 (8):36-37.
Development of Norms Through Compliance Disclosure.Björn Fasterling - 2012 - Journal of Business Ethics 106 (1):73-87.
The morality of clinical research – a case study.Torbjörn Tännsjö - 1994 - Journal of Medicine and Philosophy 19 (1):7-21.
Stimulating the development of drug treatments to improve cognition in schizophrenia.Micahel F. Green - manuscript
Determinants of Corporate Disclosure and Transparency.Stephen Yan-Leung Cheung, J. Thomas Connelly & Piman Limpaphayom - 2007 - International Corporate Responsibility Series 3:313-342.
Legal, regulatory and ethical dimensions of mandatory clinical trial registration.Ron A. Bouchard - manuscript
Determinants of Corporate Disclosure and Transparency.Stephen Yan-Leung Cheung, J. Thomas Connelly & Piman Limpaphayom - 2007 - International Corporate Responsibility Series 3:313-342.

Analytics

Added to PP
2010-09-14

Downloads
23 (#644,212)

6 months
3 (#902,269)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

Add more citations

References found in this work

A plea for pragmatism in clinical research ethics.David H. Brendel & Franklin G. Miller - 2008 - American Journal of Bioethics 8 (4):24 – 31.
Dark Remedy: The Impact of Thalidomide and Its Revival as a Vital Medicine.[author unknown] - 2002 - Journal of the History of Biology 35 (2):387-389.

Add more references